^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1037P - Taxol-ramucirumab-pembrolizumab (TRP) for immuno-resistant/refractory NSCLC
Published date:
09/05/2022
Excerpt:
11 patients benefited from the combination with clinical benefit rate (CBR, 11/14, 79%)….Of interest, one patient with both STK 11 and KEAP 1 mutations achieved PR, two patients with STK 11 mutations had SD, and 2 other patients with either KEAP 1 or STK11/KEAP1 had PD....Combination of TRP (Taxol, ramucirumab and Pembrolizumab) appears to be safe and very active against immune-resistant/refractory NSCLC...
Secondary therapy:
paclitaxel
